Adverse drug events among hospitalized medicare patients: Epidemiology and national estimates from a new approach to surveillance

Joint Commission Journal on Quality and Patient Safety

Volumn 36, Issue 1, 2010, Pages 12-21

  Classen, David C ^a,b   Jaser, Lisa ^c,d   Budnitz, Daniel S ^e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b CSC Healthcare   (United States)

^c QUALIDIGM   (United States)

^d GRIFFIN HOSPITAL   (United States)

^e NATIONAL CENTER FOR PREPAREDNESS DETECTION AND CONTROL OF INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; DIGOXIN;

AGED; ALGORITHM; ARTICLE; DRUG SURVEILLANCE PROGRAM; FEMALE; HEALTH CARE QUALITY; HOSPITAL MANAGEMENT; HUMAN; INFORMATION SYSTEM; LENGTH OF STAY; MALE; MEDICARE; MEDICATION ERROR; MORTALITY; ORGANIZATION AND MANAGEMENT; PATIENT CARE; SAFETY; STATISTICS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; DIGOXIN; FEMALE; HOSPITAL ADMINISTRATION; HOSPITAL MORTALITY; HUMANS; HYPOGLYCEMIC AGENTS; INFORMATION SYSTEMS; LENGTH OF STAY; MALE; MEDICARE; MEDICATION ERRORS; PATIENT-CENTERED CARE; QUALITY OF HEALTH CARE; SAFETY MANAGEMENT; UNITED STATES;

EID: 77449160108     PISSN: 15537250     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1553-7250(10)36003-x     Document Type: Article

References (26)

1. Institute of Medicine: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC: National Academy Press, 2001.
2. Institute of Medicine: Advancing Quality Improvement Research: Challenges and Opportunities: Workshop Summary. Chao S., Rapporteur, Forum on the Science of Health Care Quality Improvement and Implementation, Washington, DC: National Academy Press, Oct. 2007.
3. Institute of Medicine: Preventing Medication Errors. Washington, DC: National Academies Press, 2006.
4. U.S. General Accountability Office: Adverse Drug Events: The Magnitude of Health Risk Is Uncertain Because of Limited Incidence Data. Report to Congressional Requesters. Jan. 2000. http://www.ascp.com/advocacy/ briefing/upload/adegaoreport.pdf (last accessed Nov. 18, 2009).
5. Classen D.: Medication safety: Moving from illusion to reality. JAMA 289: 1154-1156, Mar. 5, 2003.
6. Classen D.C., et al.: Computerized surveillance of adverse drug events in hospital patients. JAMA 266: 2847-2851, Nov. 27, 1991.
7. Erratum in: JAMA 267: 1922, Apr. 8, 1992.
8. Rozich J.D., Haraden C.R., Resar R.K.: Adverse drug event trigger tool: A practical methodology for measuring medication related harm. Qual Saf Health Care 12: 194-200, Jun. 2003.
9. Kilbridge P., Classen D.C.: Surveillance for Adverse Drug Events: History, Methods, and Current Issues. Research Series, Issue 3, pp. 1-35. Irving, TX: VHA, Inc., Apr. 2001.
10. Morimoto T., et al.: Adverse drug events and medication errors: Detection and classification methods. Qual Saf Health Care 13: 306-314, Aug. 2004. (Pubitemid 39070900)
11. Seger A.C., Jha A.K., Bates D.W.: Adverse drug event detection in a community hospital utilizing computerized medication and laboratory data. Drug Saf 30: 817-824, Sep. 2007.
12. Kopp B.J., et al.: Medication errors and adverse drug events in an intensive care unit: Direct observation approach for detection. Grit Care Med 34: 415-425, Feb. 2006.
13. Field T. S., et al.: Strategies for detecting adverse drug events among older persons in the ambulatory setting. J Am Med Inform Assoc 11: 492-498, Nov.-Dec. 2004.
14. Kilbridge P.M., Classen D.C.: Automated surveillance for adverse events in hospitalized patients: Back to the future. Qual Saf Health Care 15: 148-149, Jun. 2006.
15. Bates, D.W., et al.: The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 277: 307-311, Jan. 22-29, 1997.
16. Eckman M.H., et al.: Making decisions about antithrombolytic therapy in heart disease: Decision analytic and cost-effectiveness issues. Chest 114: 699-714, Nov. 1998.
17. Classen D.C., et al.: Adverse drug events in hospitalized patients: Excess length of stay, extra costs, and attributable mortality. JAMA 277: 301-306, Jan. 22-29, 1997.
18. Lazarou J., Pomeranz B.H., Corey P.N.: Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279: 1200-1205, Apr. 15, 1998. (Pubitemid 28193431)
19. Leape L.L., et al., for the ADE Prevention Group: Systems analysis of adverse drug events. JAMA 274: 35-43, Jul. 5, 1995.
20. Thomas E.J., Brennan T.A.: Incidience and types of preventable adverse events in elderly population-based review of medical records. BMJ 320: 741-744, Mar. 18, 2000.
21. Budnitz D.S., et al.: Medication use leading to emergency department visits for adverse drug events in older adults. Ann Intern Med 147: 755-765, Dec. 4, 2007.
22. Smetzer J.L., et al.: Findings from the ISMP Medication Safety SelfAssessment for hospitals. It Comm J Qual Saf 29: 586-597, Nov, 2003.
23. The Joint Commission: The Joint Commission announces the 2008 National Patient Safety Goals and Requirements. It Comm Perspect 27: 1, 9-22, Jul. 2007.
24. Hackbarth A.D., et al.: The hard count: Calculating lives saved in the 100,000 Lives Campaign. ACP Guide for Hospitalists, pp. 1-5, Apr. 2006. http://www.ihi.org/IHI/Topics/Improvenient/SpreadiigChanges/Literature/ ThehardcountCalculatinglivessavedinthe100000LivesCampaign.htm (last accessed Nov. 19, 2009).
25. Hunt D.R., et al.: Fundamentals of Medicare patient safety surveillance: Intent, relevance, and transparency. Advances in Patient Safety: From Research to Implementation, vol. 2, Feb. 2005. http://www.ahrq.gov/downloads/pub/ advances/vol2/Hunt.pdf (last accessed Nov. 18, 2009).
26. Budnitz D.S., et al.: National surveillance of emergency department visits for outpatient adverse drug events. JAMA 296: 1858-1866, Oct. 18, 2006.